PipelineReview.com - Target Pipelines

Show Cart

Target Pipelines

Results 11 - 20 of 67

Aug 2018 CD40 Antagonists & CD40L Inhibitors – Target Pipeline List 08/2018

Aug 2018 Myostatin Inhibitors – Target Pipeline List 08/2018

Aug 2018 Interleukin-2 Receptor Agonists – Target Pipeline List 08/2018

Aug 2018 LRRK2 Inhibitors – Target Pipeline List 08/2018

Jul 2018 CXCR2, CCR2 & CCR4 Chemokine Receptor Antagonists – Target Pipeline List 07/2018

Jul 2018 CXCR4 Chemokine Receptor Antagonists – Target Pipeline List 07/2018

Jul 2018 Aryl Hydrocarbon Receptor (AHR) Agonists & Antagonists – Target Pipeline List 07/2018

Jul 2018 Novel IDO & TDO Inhibitors – Target Pipeline List 07/2018

Jul 2018 CSF-1R ( Colony Stimulating Factor 1 Receptor) Antagonists – Target Pipeline List 07/2018

Jul 2018 TGF-beta Inhibitors – Target Pipeline List 07/2018

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing